Skip to content
2000
Volume 23, Issue 3
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Introduction

Approximately 3% of patients treated with heparinoids develop heparin-induced thrombocytopenia (HIT). Although HIT is characterized by thrombocytopenia, type 2 HIT is associated with a high risk of thrombotic events in approximately 30-75% of cases. In some patients, thrombocytopenia represents the primary clinical manifestation of HIT. Early diagnosis of HIT is critical to prevent thrombotic complications by allowing timely replacement of heparin with an alternative anticoagulant. Clinical observations suggest a potential gap in the diagnosis and management of HIT among patients receiving heparinoid therapy in Iran.

Aims

Hence, this study aimed to compile and analyze published data on the frequency and prevalence of HIT across various provinces in Iran, a representative developing country. The aim of this systematic review was to identify and highlight potential gaps in the diagnosis of HIT within different regions of the country.

Methods

To investigate this hypothesis, a systematic review was conducted to assess the prevalence of HIT and the adequacy of its detection in the country. Literature searches were performed using PubMed, Google Scholar, Web of Science, and local databases, yielding 81 articles. Following a rigorous evaluation, five studies met the inclusion criteria for the systematic review. The pooled analysis revealed an estimated HIT prevalence of 6.93% among the studied population. The mean age of participants ranged between 58 and 69 years, falling within the late-adolescent to early-elderly spectrum. The overall male-to-female ratio was 175:121 (59.2% male . 40.8% female).

Results

This study highlights a significant gap in the diagnosis of HIT in the country, suggesting that similar challenges may exist in other developing countries.

Conclusion

In conclusion, addressing this issue requires increased clinical awareness and improved diagnostic strategies to mitigate associated risks.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/0118715257358047250226044013
2025-03-13
2026-02-05

  • From This Site

    /content/journals/chamc/10.2174/0118715257358047250226044013
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HoganM. BergerJ.S. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management.Vasc. Med.202025216017310.1177/1358863X19898253 32195628
     [Google Scholar]
  2. HoffmanM. Heparins: Clinical use and laboratory monitoring.Lab. Med.2010411062162610.1309/LMSXWC3A4LBIJP2B
     [Google Scholar]
  3. BoshkovL.K. WarkentinT.E. HaywardC.P.M. AndrewM. KeltonJ.G. Heparin‐induced thrombocytopenia and thrombosis: Clinical and laboratory studies.Br. J. Haematol.199384232232810.1111/j.1365‑2141.1993.tb03072.x 8398837
     [Google Scholar]
  4. FathiM. Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways.Glob. Cardiol. Sci. Pract.2018201821510.21542/gcsp.2018.15
     [Google Scholar]
  5. WarkentinT.E. Clinical presentation of heparin-induced thrombocytopenia.Semin. Hematol.1998354-5916 9855179
     [Google Scholar]
  6. WarkentinT.E. SheppardJ.A.I. Heels-AnsdellD. MarshallJ.C. McIntyreL. RochaM.G. MehtaS. DaviesA.R. BerstenA.D. CrozierT.M. ErnestD. VlahakisN.E. HallR.I. WoodG.G. PoirierG. CrowtherM.A. CookD.J. Heparin-induced thrombocytopenia in medical surgical critical illness.Chest2013144384885810.1378/chest.13‑0057 23722881
     [Google Scholar]
  7. WarkentinT.E. SheppardJ.A.I. MooreJ.C. CookR.J. KeltonJ.G. Studies of the immune response in heparin-induced thrombocytopenia.Blood2009113204963496910.1182/blood‑2008‑10‑186064 19144981
     [Google Scholar]
  8. WarkentinT.E. HaywardC. BoshkovL.K. SantosA.V. SheppardJ.A. BodeA.P. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia.Blood199484113691369910.1182/blood.V84.11.3691.bloodjournal84113691
     [Google Scholar]
  9. NewmanP.M. ChongB.H. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4–heparin antibodies to platelets and the resultant platelet activation.Blood200096118218710.1182/blood.V96.1.182 10891449
     [Google Scholar]
  10. JurkK. KehrelB.E. Platelets: Physiology and biochemistry.Semin. Thromb. Hemost.200538139210.1055/s‑2005‑916671
     [Google Scholar]
  11. FalatiS. LiuQ. GrossP. Merrill-SkoloffG. ChouJ. VandendriesE. CeliA. CroceK. FurieB.C. FurieB. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.J. Exp. Med.2003197111585159810.1084/jem.20021868 12782720
     [Google Scholar]
  12. LeviM. van der PollT. SchultzM. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Seminars in immunopathology.Springer201216717910.1007/s00281‑011‑0283‑7
     [Google Scholar]
  13. LeviM. Current understanding of disseminated intravascular coagulation.Br. J. Haematol.2004124556757610.1046/j.1365‑2141.2003.04790.x 14871243
     [Google Scholar]
  14. ArepallyG.M. CinesD.B. Pathogenesis of heparin-induced thrombocytopenia.Transl. Res.202022513114010.1016/j.trsl.2020.04.014 32417430
     [Google Scholar]
  15. LinkinsL-A. WarkentinT.E. Heparin-induced thrombocytopenia: Real-world issues.Semin. Thromb. Hemost.201137665366310.1055/s‑0031‑1291375
     [Google Scholar]
  16. RostamiM. MansouritorghabehH. D-dimer level in COVID-19 infection: A systematic review.Expert Rev. Hematol.202013111265127510.1080/17474086.2020.1831383 32997543
     [Google Scholar]
  17. OuzzaniM. HammadyH. FedorowiczZ. ElmagarmidA. Rayyan: A web and mobile app for systematic reviews.Syst. Rev.20165121010.1186/s13643‑016‑0384‑4 27919275
     [Google Scholar]
  18. AhmadinejadM. ShahbaziM. CheginiA. Heparin-induced thrombocytopenia in iranian cardiac surgery patients using the 4Ts clinical scoring system and laboratory methods.Int. J. Hematol. Oncol. Stem Cell Res.202115423023810.18502/ijhoscr.v15i4.7478 35291665
     [Google Scholar]
  19. NasiripourS. SaifM. FarasatinasabM. EmamiS. AmouzegarA. BasiA. MokhtariM. Dabigatran as a treatment option for heparin‐induced thrombocytopenia.J. Clin. Pharmacol.201959110711110.1002/jcph.1300 30285276
     [Google Scholar]
  20. FarasatinasabM. BalouchzehiS. MoghaddamO.M. AnsarinejadN. MohammadiM. NasiripourS. An open‐label, single‐arm, pilot intervention study to assess the efficacy and safety of apixaban in heparin‐induced thrombocytopenia.J. Clin. Pharmacol.202262111379138410.1002/jcph.2096 35656855
     [Google Scholar]
  21. FarasatinasabM. ZareiB. MoghtadaeiM. NasiripourS. AnsarinejadN. ZareiM. Rivaroxaban as an alternative agent for heparin‐induced thrombocytopenia.J. Clin. Pharmacol.202060101362136610.1002/jcph.1635 32519800
     [Google Scholar]
  22. ShahbaziM. AhmadinejadM. Heparin induced thrombocytopenia. Sci. J. Iran Blood.Transfus. Organ201916133148
     [Google Scholar]
  23. FarsadF. ForoughiniaF. GholamiK. AhmadiS. Usefulness of Danaparoid sodium in patients with Heparin-induced thrombocytopenia after cardiac surgery.J. Res. Pharm. Pract.201542737810.4103/2279‑042X.155754 25984544
     [Google Scholar]
  24. EmamiS.A.H. KabiriK. SayediS.M. TaghaddosiM. MousaviS.G.A. Prevalence of Heparin-induced Thrombocytopenia in patients with cardiovascular disease admitted to Shahid Beheshti Hospital in Kashan in 1999.Feyz. Med. Sci. J.200155053
     [Google Scholar]
  25. NoughH. Khodadadi ZadehA. ArefM. Incidence of Thrombocytopenia Induced by Two Methods of Intravenous Heparin injection in Patients with Acute Coronary Syndrome.Sci. Mag. Danishcheh. Bezishek. Rafsanjan20054916
     [Google Scholar]
  26. RostamiM. MansouritorghabehH. Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis.J. Thromb. Thrombolysis202356224125210.1007/s11239‑023‑02827‑5 37219826
     [Google Scholar]
  27. Iran Population.Available from: https://www.worldometers.info/world-population/iran-population/ 2023
  28. WarkentinT.E. How I diagnose and manage HIT.Hematology. Am. Soc. Hematol. Educ. Program.2011201114314910.1182/asheducation‑2011.1.143
     [Google Scholar]
  29. FavaloroE.J. Toward improved diagnosis of HIT.Blood2015126556356410.1182/blood‑2015‑05‑644740 26228166
     [Google Scholar]
  30. MarchettiM. BarelliS. ZermattenM.G. Monnin-RespenF. Matthey-GuiraoE. NicolasN. GomezF. GoodyerM. GerschheimerC. AlberioL. Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia.Blood202013514blood. 201900284510.1182/blood.201900284531945147
     [Google Scholar]
  31. Samuelson BannowB. WaradD.M. JonesC.G. PechauerS.M. CurtisB.R. BougieD.W. SharmaR. GrillD.E. RedmanM.W. KhalighiP.R. LegerR.R. PruthiR.K. ChenD. SabathD.E. AsterR.H. GarciaD.A. PadmanabhanA. A prospective, blinded study of a PF4-dependent assay for HIT diagnosis.Blood202113781082108910.1182/blood.2020008195 32898858
     [Google Scholar]
  32. LarsenE.L. NiliusH. StudtJ.D. TsakirisD.A. GreinacherA. MendezA. SchmidtA. WuilleminW.A. GerberB. VishnuP. GrafL. Kremer HovingaJ.A. GoetzeJ.P. BakchoulT. NaglerM. Accuracy of diagnosing heparin-induced thrombocytopenia.JAMA Netw. Open202473e243786e24378610.1001/jamanetworkopen.2024.3786 38530310
     [Google Scholar]
  33. CirbusK. SimoneP. Austin SzwakJ. Rivaroxaban and apixaban for the treatment of suspected or confirmed heparin‐induced thrombocytopenia.J. Clin. Pharm. Ther.202247111211810.1111/jcpt.13537 34704283
     [Google Scholar]
  34. LinkinsL.A. WarkentinT.E. PaiM. ShivakumarS. ManjiR.A. WellsP.S. CrowtherM.A. Design of the rivaroxaban for heparin-induced thrombocytopenia study.J. Thromb. Thrombolysis201438448549210.1007/s11239‑014‑1064‑7 24549975
     [Google Scholar]
  35. SartoriM. FavarettoE. CiniM. LegnaniC. CosmiB. Rivaroxaban in the treatment of heparin-induced thrombocytopenia.J. Thromb. Thrombolysis201540339239410.1007/s11239‑015‑1208‑4 25804370
     [Google Scholar]
  36. LewisB.E. WallisD.E. LeyaF. HurstingM.J. KeltonJ.G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.Arch. Intern. Med.2003163151849185610.1001/archinte.163.15.1849 12912723
     [Google Scholar]
  37. KosterA. FischerK.G. HarderS. MertzlufftF. The direct thrombin inhibitor argatroban: A review of its use in patients with and without HIT.Biologics200712105112 19707320
     [Google Scholar]
  38. HoP.J. SiordiaJ.A. Dabigatran approaching the realm of heparin-induced thrombocytopenia.Blood Res.2016512778710.5045/br.2016.51.2.77 27382551
     [Google Scholar]
  39. SzydaŁ.S. KlosinskaM.K. PoninskaN.P. Mrozowska-PerugaE.M.P. KasprzakJ.D.K. Dabigatran as first-line treatment for heparin-induced thrombocytopenia in the intensive cardiac care setting.Eur. Heart J.2021421)(Suppl. 1ehab724.298210.1093/eurheartj/ehab724.2982
     [Google Scholar]
  40. KosterA. WengY. BöttcherW. GromannT. KuppeH. HetzerR. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT.Ann. Thorac. Surg.20078351865186710.1016/j.athoracsur.2006.11.051 17462416
     [Google Scholar]
  41. JosephL. CasanegraA.I. DhariwalM. SmithM.A. RajuM.G. MilitelloM.A. GomesM.P. GornikH.L. BartholomewJ.R. Bivalirudin for the treatment of patients with confirmed or suspected heparin‐induced thrombocytopenia.J. Thromb. Haemost.20141271044105310.1111/jth.12592 24766902
     [Google Scholar]
  42. KuoK.H.M. KovacsM.J. Fondaparinux: A potential new therapy for HIT.Hematology200510427127510.1080/10245330500093492 16085538
     [Google Scholar]
  43. KuoK. KovacsM. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux.Thromb. Haemost.2005935999100010.1055/s‑0037‑1616573 15886823
     [Google Scholar]
  44. WarkentinT.E. Fondaparinux: Does it cause HIT? can it treat HIT?Expert Rev. Hematol.20103556758110.1586/ehm.10.54 21083474
     [Google Scholar]
  45. ChongB.H. MagnaniH.N. Danaparoid for the treatment of heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia.CRC Press2012478500
     [Google Scholar]
  46. ChongB.H. CadeJ.F. MagnaniH. ManoharanA. OldmeadowM. ArthurC. RickardK. GalloJ. LloydJ. SeshadriP. GallusA.S. ChestermanC.N. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: A clinical outcome study.Thromb. Haemost.200186111170117510.1055/s‑0037‑1616046 11816702
     [Google Scholar]
/content/journals/chamc/10.2174/0118715257358047250226044013
Loading
The Challenge of Detecting Heparin-induced Thrombocytopenia (HIT) in a Developing Country: A Systematic Review
Cardiovasc. Hematol. Agents Med. Chem. 23, 202 (2025); https://doi.org/10.2174/0118715257358047250226044013
/content/journals/chamc/10.2174/0118715257358047250226044013
/content/journals/chamc/10.2174/0118715257358047250226044013
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): Heparin-induced thrombocytopenia (HIT); heparinoids; Iran; platelet; thrombocytopenia; thrombosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test